New MHRA–FDA collaboration aims to boost patient access and AI safety
New MHRA–FDA collaboration aims to boost patient access and AI safety
Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026
New survey reveals critical gaps in access to testing and timely care
Six new treatments aim to improve patient outcomes across key areas
UPSIDE study explores early transplant therapy for rare autoimmune disease
Early-stage study reveals strong immune response and safety profile for ACI-35.030
EU phase 3 data shows major gains in dialysis access performance
Acella and Neuvosyn report positive results for investigational DTE therapy
GM CRDC begins trials to assess real-world effectiveness of respiratory vaccines
CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis
EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment
BlueRock begins phase 3 study of bemdaneprocel in Parkinson’s disease
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
Preclinical results highlight potential of glycosaminoglycan-based therapy
Data from trials highlight long-term disease control and quality of life improvements